CAH · Cardinal Health Inc.
AI read · Good for CAH
The AI's read
Cardinal beat Q4 EPS and raised fiscal posture while the CEO said the company now exclusively serves nearly half the cell-and-gene therapy market. They also boosted buybacks and opened a specialty pharmacy to support complex therapies. The market moved only about 2.68% so far and RSI is 43.74, so the upside isn't fully priced in and the stock isn't stretched. Revenue missed estimates but operating earnings jumped 30%, which supports the take. We lean bullish because exclusivity in an emerging, high-margin niche plus a $5B buyback creates asymmetric upside and EPS support. Conviction is high but respect execution and competitive risk around specialty logistics.